Urs Breitenstein
6 Papers
Urs Breitenstein is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Abstract P2-01-01: Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine
Rupert Bartsch,Nadia Harbeck,D. Wrobel,Matthias Zaiss,J. Terhaag,Dagmar Guth,A. Distelrath,Rachel Wuerstlein,Mark-Oliver Zahn,Diana Lüftner,Michael Schwitter,Marija Balic,Christian Jackisch,Volkmar Müller,Gabriel Rinnerthaler,Marc Schmitz,Khalid Zaman,Timo Schinköthe,Anna Resch,Urs Breitenstein +19 more
TL;DR: In this paper , a preplanned interim analysis based on 200 enrolled patients was conducted to evaluate the effect of neratinib on the 5-year invasive disease-free survival (iDFS) rate.
1
Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib
Diana Lüftner,Rupert Bartsch,Urs Breitenstein,Marija Balic,Christian Jackisch,Volkmar Müller,Gabriel Rinnerthaler,Marcus Schmidt,Michael Schwitter,Khalid Zaman,D. Wrobel,Dagmar Guth,J. Terhaag,Matthias Zaiss,Timo Schinköthe,Nadia Harbeck +15 more
TL;DR: The results of the first interim analysis present a preliminary snapshot of the current treatment landscape and real-life neratinib use in Germany and Austria, as well as detailed patient and disease characteristics, details on prior trastuzumab-based therapies, and first safety and tolerability data of real-world neratinIB use.
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)
Erica L. Mayer,Christian Fesl,Dominik Hlauschek,Laura García-Estévez,Harold J. Burstein,Nicholas Zdenkowski,Viktor Wette,Kathy D. Miller,Marija Balic,Ingrid A. Mayer,David Cameron,Eric P. Winer,Jose Juan Ponce Lorenzo,Diana Lake,Gunda Pristauz-Telsnigg,Tufia C. Haddad,Lois E. Shepherd,Hiroji Iwata,Matthew P. Goetz,Fatima Cardoso,Tiffany A. Traina,Danusha Sabanathan,Urs Breitenstein,Kerstin Ackerl,Otto Metzger Filho,Karin Zehetner,Kadine Solomon,Sarra El-Abed,Katherine P. Theall,Dongrui Ray Lu,Amylou C. Dueck,Michael Gnant,Angela DeMichele +32 more
TL;DR: Despite observed rates of discontinuation in PALLAS, analyses suggest that the lack of significant iDFS difference between arms was not directly related to inadequate palbociclib exposure and the challenge of introducing novel adjuvant treatments, and the need for interventions to improve persistence with oral cancer therapies.
Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment.
Daniel Betticher,Geoffrey Delmore,Urs Breitenstein,Sandro Anchisi,Beatrice Zimmerli-Schwab,A. Müller,Roger von Moos,Anne Marguerite Hügli-Dayer,Hubert Schefer,Sereina Bodenmann,Vera Bühler,Ralph R. Trueb +11 more
TL;DR: In this first comparison published to date, both PAX and CC offer efficacious protection against hair loss, in particular when docetaxel is administered in a 3-weekly interval.
Neratinib as extended adjuvant treatment of HER2-positive/HR-positive early breast cancer patients in Germany, Austria and Switzerland: interim results of the prospective, observational ELEANOR study
Nadia Harbeck,D. Wrobel,Matthias Zaiss,J. Terhaag,Dagmar Guth,A. Distelrath,Mark-Oliver Zahn,Rachel Würstlein,Andreas Lorenz,Rupert Bartsch,Urs Breitenstein,Michael Schwitter,Marija Balic,Christian Jackisch,Volkmar Müller,Gabriel Rinnerthaler,Marcus Schmidt,Khalil Zaman,Timo Schinköthe,Anna Resch,Roberta Valenti,D Lueftner +21 more
TL;DR: The interim results suggest that neratinib as an extended adjuvant is a feasible option after various anti-HER2 pretreatments and that its tolerability can be managed and improved with proactive diarrhea management.